Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination

Epilepsia

Volumn 48, Issue 7, 2007, Pages 1406-1408

  Capablo, Jose L ^a   Franco, Rafael ^b   De Cabezón, Alicia Sáenz ^a   Alfonso, Pilar ^c   Pocovi, Miguel ^c   Giraldo, Pilar ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b Hospital de Punta Europa   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Combination therapy; Gaucher disease; Imiglucerase; Miglustat; Neurologic manifestation

Indexed keywords

ALGLUCERASE; CHITOTRIOSIDASE; CLONAZEPAM; IMIGLUCERASE; LAMOTRIGINE; MIGLUSTAT; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DETERIORATION; DIET; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSTONIA; ELECTROENCEPHALOGRAPHY; ENZYME REPLACEMENT; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GAUCHER DISEASE; GRAND MAL SEIZURE; HUMAN; MALE; MYOCLONUS EPILEPSY; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; VISCERA;

1-DEOXYNOJIRIMYCIN; ADULT; COMORBIDITY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSTONIA; ELECTROENCEPHALOGRAPHY; ENZYME INHIBITORS; EPILEPSIES, MYOCLONIC; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MALE; NERVOUS SYSTEM DISEASES; RECOMBINANT PROTEINS; SYNDROME; TREATMENT OUTCOME;

EID: 34447295360     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01074.x     Document Type: Article

References (10)

1. Alfonso P, Pampin S, Estrada J, Rodriguez-Rey JC, Giraldo P, Sancho J, Pocovi M 2005) Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells, Molecules and Disease 35 : 268 276.
2. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murria GJ, Parkev RI, Argoff CE 1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. New England Journal of Medicine 324 : 1464 1470.
3. Futerman AH. (2006) Intracellular trafficking of sphingolipids: relationship to biosynthesis Biochimica et Biophysica Acta. Aug 15 on line.
4. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M 2006) Short term effect in an every day clinical use of miglustat in naïve or previously treated type 1 Gaucher disease. Haematologica 91 : 125 128.
5. Giraldo P, Solano V, Perez-Calvo JI, Giralt M, Rubio-Felix D, and Spanish group on Gaucher disease 2005) Quality of life related to type 1 Gaucher disease: Spanish experience. Quality of Life Research 14 453 462.
6. Kowarz L, Goker-Alpan O, Banerjee-Basu S, LaMarca ME, Kinlaw L, Schiffmann R, Baxevanis AD, Sidransky E 2005) Gaucher mutation N188S is associated with myoclonic epilepsy. Human Mutation 26 : 271 273.
7. Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky E, Schiffmann R, Futerman AH 2005) Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiological Disease 18 : 83 88.
8. Verghese J, Goldberg RF, Desnick RJ, Grace ME, Goldman JE, Lee SC, Dickson DW, Rapin I 2000) Myoclonus from selective dentate nucleus degeneration in type 3 Gaucher disease. Archives of Neurology 57 : 389 395.
9. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A, Lwin A, Colegial C, Allman JM, Schiffmann R 2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Molecular Genetics and Metabolism 82 : 192 207.
10. Wraith JE. (2006) Limitations of enzyme replacement therapy: current and future. Journal of Inherited Metabolic Disease (2-3 442 447.